Table 3a Alemtuzumab-treated patients with one or more significant change of antivirus IgG level, values at 6–12 months post-therapy compared with baseline

From: Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia

Patient

Alemtuzumab (n=16)a

 

CMV IgG

VZV IgG

Measles IgG

EBV p107 IgG

EBV VCA IgG

A4

0

0

0

0

+

A5

0

0

0

0

+

A8 (=C9)

−b

−

−

−

0

A12

0

0

−

0

0

A14

0

0

0

0

−

A15

0

0

+

−

0

A16

+

0

0

0

0

A18

0

+c

0

0

0

Total

1 decrease

1 decrease

2 decrease

2 decrease

1 decrease

 

1 increase

1 increase

1 increase

 

2 increase

  1. Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; IgG, immunoglobulin G; VZV, varicella zoster virus; 0, no significant change; −, significant decrease; +, significant increase.
  2. aTwo of the totally 18 patients were excluded; one because of IV γ-globulin treatment (A1) and the other because of shorter follow-up than 6 months (A16). N=15 for EBV p107G because of sample shortage in one patient.
  3. bSymptomatic reactivation, grade I, 2 months after start of treatment.
  4. cSymptomatic reactivation, grade I, 10 months after end of treatment.
  5. All, but patient A16, responded to alemtuzumab treatment.
Back to article page